14.11.2023 - LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved .
Issue of Shares LONDON and SALT LAKE CITY - July 17, 2023 - Renalytix plc , announces the repayment of $1.06 million of the Company s convertible bond, further details of which.
Directorate Change Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors LONDON and SALT LAKE CITY - July 3, 2023 - Renalytix plc ,.